Tomoregulin-2 and CD3 receptor complex (TMEFF2 and CD3 receptor complex)

The “Tomoregulin-2 and CD3 receptor complex” refers to the functional pair of the transmembrane protein **Tomoregulin-2 (TMEFF2)**—a type I transmembrane protein with EGF-like and follistatin domains—and the **CD3 receptor complex**, an essential component of the T-cell receptor (TCR) complex required for T cell activation and immune signaling. TMEFF2 has roles in signal transduction and has been implicated in the regulation of cell proliferation and growth factor signaling, with dual roles reported in tumor promotion or suppression depending on context; its expression and methylation are being explored as cancer biomarkers[2]. The CD3 complex (composed of CD3γ, CD3δ, CD3ε, and CD3ζ chains) is essential for T cell activation and is a well-validated immunotherapy target[1][3][6]. These two proteins are artificially brought together in therapeutic contexts—most notably via bi-specific antibodies (BiTEs)—to drive the cytotoxic activity of T-cells toward TMEFF2-expressing tumors[4][5]. Existing data support their validity as dual immunotherapeutic targets, but “TMEFF2 and CD3 receptor complex” is not a naturally occurring protein complex; rather, it is a functional pair used in therapeutic engineering (e.g., bispecific antibodies). Additional notes: - **is_incorrect: true** because “TMEFF2 and CD3 receptor complex” does not represent a single, naturally existing molecular complex. The naming reflects a dual-targeted approach in immunotherapy rather than a single canonical target. Both TMEFF2 and the CD3 receptor complex are individually recognized, but not as a natural molecular complex[3][4][5][7]. - JNJ-70218902 is a notable bi-specific antibody example targeting both human TMEFF2 and CD3 for cancer immunotherapy, particularly in prostate cancer[4][5]. - Major safety risks derive from T-cell redirection, with typical immune-related adverse effects[5].

Other names

TMEFF2 (Tomoregulin-2)CD3 complexCD3 T cell receptor complex

T-cell redirection and activation against TMEFF2-expressing tumor cells by binding both TMEFF2 (tumor) and CD3 (T cell), leading to T-cell mediated cytotoxicity